Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > Prostate Cancer Therapeutics Market

Prostate Cancer Therapeutics Market – By Therapy (Hormonal, Chemotherapy, Immunotherapy), Drug Class (Androgen Receptor Inhibitor, GnRH Receptor Antagonist, PARP), Route of Administration (Oral, Injectable), Distribution Channel & Forecast, 2024 – 2032

  • Report ID: GMI10189
  • Published Date: Jul 2024
  • Report Format: PDF

Prostate Cancer Therapeutics Market Size

Prostate Cancer Therapeutics Market size was valued at USD 11.7 billion in 2023 and is expected to exhibit growth at a CAGR of 8.8% from 2024 to 2032. High market growth can be attributed to the ongoing advancements in treatment modalities, increasing prevalence of prostate cancer, rising awareness, and screening programs, and expanding pipeline of novel therapies, among other contributing factors.

Prostate Cancer Therapeutics Market

Moreover, prostate cancer is one of the most prevalent tumors diagnosed in males globally. The aging population, as well as changes in lifestyle factors such as diet, smoking, and physical activity, all contribute to an expansion of prostate cancer incidence and prevalence. For instance, according to the National Institutes of Health (NIH), it is estimated that new cases of prostate cancer will reach 299,010 by 2024 in the U.S. As the number of confirmed cases grows, so does the demand for effective therapeutic options.

Furthermore, public awareness campaigns, educational initiatives, and government-sponsored screening programs raise awareness about prostate cancer risk factors, symptoms, and the importance of early detection. For instance, in August 2023, the George Washington University (GW) Cancer Center launched a prostate cancer awareness campaign. This health awareness social media toolkit could help cancer control organizations use evidence-based strategies to detect prostate cancer. Thus, improved awareness leads to higher rates of screening and diagnosis, driving the demand for prostate cancer therapeutics.

Prostate cancer therapeutics refer to the various treatment options and strategies employed to manage and treat prostate cancer, a malignancy that develops in the prostate gland of males. The aim of prostate cancer therapeutics is to eliminate or manage the cancerous cells, reduce symptoms, improve quality of life, and prolong survival for patients diagnosed with prostate cancer.

Prostate Cancer Therapeutics Market Trends

The prostate cancer therapeutics industry is experiencing several notable trends that are shaping its growth and development. Factors such as continuous innovations in therapies, increased focus on personalized medicine, rise of minimally invasive treatments, and growing demand for integrated artificial intelligence in healthcare and machine learning, among other factors are propelling the industry growth.

  • Further, there is a growing focus on patient-centric care approaches, involving shared decision-making between healthcare providers and patients. Patient preferences, quality of life considerations, and treatment goals play a significant role in treatment planning and selection of therapeutics.
  • Moreover, combination therapies that combine different treatment modalities, such as surgery with radiotherapy or chemotherapy with immunotherapy, are increasingly used to enhance treatment efficacy and overcome resistance mechanisms in prostate cancer, thereby aforementioned factors are expected to drive the market.

Prostate Cancer Therapeutics Market Analysis

Prostate Cancer Therapeutics Market, By Therapy, 2021 - 2032 (USD Billion)

Based on therapy, the market is classified into hormonal therapy, chemotherapy, immunotherapy, targeted therapy and other therapies. The hormonal therapy generated the highest revenue of USD 8.1 billion in 2023.

  • Hormonal therapy is effective in reducing levels of androgens (male hormones) such as testosterone, which fuel the growth of prostate cancer cells. By lowering androgen levels, hormonal therapy can slow down or halt the progression of prostate cancer, alleviate symptoms, and improve survival outcomes in patients.
  • Moreover, advances in hormonal therapy, including the development of new agents such as next-generation anti-androgens (e.g., enzalutamide and apalutamide) and novel hormonal therapies (e.g., abiraterone acetate), have expanded treatment options and improved efficacy.
  • These advancements drive market growth by offering more targeted and effective therapies with fewer side effects compared to traditional treatments.


Prostate Cancer Therapeutics Market, By Drug Class (2023)

Based on drug class, the prostate cancer therapeutics market is classified into androgen receptor inhibitors, GnRH receptor antagonist, PARP inhibitor, immune checkpoint inhibitors, and other drug classes. The androgen receptor inhibitors segment dominated the market in 2023 with a market share of 35%.

  • ARIs are also utilized in the treatment of castration-resistant prostate cancer, where cancer cells continue to grow despite ADT. These agents provide a therapeutic option to manage CRPC by targeting androgen receptor signaling pathways and overcoming resistance mechanisms that develop over time.
  • Furthermore, they are generally well-tolerated compared to traditional chemotherapy, offering patients improved quality of life with fewer severe side effects. This aspect enhances patient compliance and adherence to treatment regimens, especially in cases where long-term therapy is necessary.

Based on route of administration, the prostate cancer therapeutics market is classified into oral and injectable. The oral segment dominated the market and is expected to grow at a pace of 8.6% CAGR between 2024 – 2032.

  • Oral therapies provide patients with a convenient and non-invasive treatment option compared to injectable therapies. Patients can self-administer oral medications at home, reducing the need for frequent clinic visits and enhancing treatment adherence. This convenience improves patient satisfaction and overall quality of life during cancer treatment.
  • Moreover, the pharmaceutical companies continue to invest in research and development of oral therapies for prostate cancer, leading to the discovery of new molecular targets and novel therapeutic agents. These advancements expand the treatment options available to patients, offering improved efficacy, reduced side effects, and better disease control.

Based on distribution channel, the prostate cancer therapeutics market is segmented into hospital pharmacy, brick and mortar, and e-commerce. The hospital pharmacy segment dominated the market in 2023 and is anticipated to reach USD 15.7 billion by the end of forecast period.

  • Hospital pharmacies provide specialized care and expertise in managing complex therapies, including those used in the treatment of prostate cancer. Pharmacists and pharmacy staff are trained to handle oncology medications, ensuring safe and effective administration while monitoring for potential drug interactions and adverse effects.
  • Furthermore, these pharmacies have access to a wide range of specialized therapies and advanced treatment options for prostate cancer, including chemotherapy agents, hormonal therapies, immunotherapies, and targeted therapies. They ensure timely availability of medications, including investigational drugs through clinical trials, to meet the evolving needs of prostate cancer patients.


North America Prostate Cancer Therapeutics Market, 2021 – 2032 (USD Billion)

North America prostate cancer therapeutics market accounted for USD 4.6 billion market revenue in 2023 and is anticipated to grow at CAGR of 8.4% between 2024 and 2032.

  • North America boasts advanced healthcare infrastructure, including well-equipped hospitals, specialized cancer centers, and comprehensive oncology care facilities. This infrastructure supports early diagnosis, timely treatment, and access to innovative therapies for prostate cancer patients, thereby driving market growth.
  • The region has a relatively high healthcare expenditure, and governments and private organizations continue to invest in innovative therapies for cancer treatment, including prostate cancer. This investment supports the development, commercialization, and adoption of new drugs in the market.
  • For instance, according to the data by Centers for Medicare and Medicaid Services (CMS.gov) shows that in 2023, the U.S. spent approximately USD 4.7 trillion on healthcare, constituting 18% of the national economy. It is projected that total healthcare expenses, including private and governmental spending, will increase from USD 4.7 trillion in 2023 to USD 7.2 trillion by 2031, with an average growth rate of 5.5% per year.

Germany prostate cancer therapeutics market is projected to grow remarkably in the coming years.

  • Germany is a hub for clinical research and development (R&D) in oncology, including prostate cancer therapeutics. Academic institutions, pharmaceutical companies, and research organizations collaborate on clinical trials to evaluate novel drugs,  cancer biomarkers, and treatment strategies.
  • This collaborative research environment drives innovation, supports evidence-based medicine, and accelerates the introduction of new therapies into clinical practice.
  • Additionally, the country emphasizes patient-centered care models, focusing on individualized treatment plans, shared decision-making, and patient empowerment. Oncologists and healthcare providers prioritize treatment regimens that optimize outcomes while considering patient preferences, quality of life, and treatment adherence.

Japan holds a dominant position in the Asia Pacific prostate cancer therapeutics market.

  • Japan has a rapidly aging population, with a significant proportion of elderly men who are at higher risk of developing prostate cancer. The increasing incidence of prostate cancer drives the demand for effective treatment options and therapeutics in the country.
  • Furthermore, the regulatory framework in country ensures rigorous evaluation and approval processes for prostate cancer therapeutics. Expedited review pathways for breakthrough therapies and innovative treatment modalities facilitate market entry and adoption of new treatments, benefiting patients and healthcare providers.

Prostate Cancer Therapeutics Market Share

The market is characterized by a diverse range of treatments aimed at managing various stages of prostate cancer. Hormonal therapies like androgen deprivation therapy (ADT) and androgen receptor inhibitors (ARIs) dominate, addressing hormone-sensitive and castration-resistant forms. Chemotherapy, immunotherapy, and targeted therapies such as PARP inhibitors are also significant. Market dynamics are driven by ongoing research, regulatory developments, and advancements in personalized medicine. North America and Europe lead in market share due to advanced healthcare infrastructures and high disease prevalence, while emerging regions show growing potential with expanding healthcare access and increasing adoption of innovative therapies.

Prostate Cancer Therapeutics Market Companies

Prominent players operating in the prostate cancer therapeutics industry include:

  • Astellas Pharma Inc.
  • AstraZeneca Plc
  • Bayer AG
  • Dendreon Pharmaceuticals LLC.
  • Exelixis, Inc
  • Ferring B.V.
  • GlaxoSmithKline Plc
  • Ipsen Pharma
  • Johnson & Johnson
  • Novartis AG
  • Pfizer Inc.
  • Sanofi S.A
  • Sumitomo Pharma America, Inc.
  • Takeda Pharmaceutical Company Limited
  • Tolmar Inc.

Prostate Cancer Therapeutics Industry News:

  • In April 2024, Astellas Pharma Inc. received approval from the European Commission to expand the label for XTANDI (enzalutamide). This approval allows XTANDI to be used either alone or in combination with androgen deprivation therapy (ADT) for treating adult men diagnosed with high-risk biochemical recurrent (BCR), non-metastatic hormone-sensitive prostate cancer (nmHSPC) who are not suitable candidates for salvage radiotherapy. This extension broadens the treatment options available to this specific patient population, offering a new therapeutic approach to manage their condition effectively.
  • In February 2023, Pfizer reported positive findings from the Phase 3 TALAPRO-2 trial of TALZENNA (talazoparib), an oral PARP inhibitor, in combination with XTANDI (enzalutamide). These results highlight the potential of combining TALZENNA with XTANDI as a promising treatment option for patients with mCRPC, addressing an unmet medical need in advanced prostate cancer therapy.

The prostate cancer therapeutics market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2021 – 2032 for the following segments:

Click here to Buy Section of this Report

Market, By Therapy

  • Hormonal therapy
  • Chemotherapy
  • Immunotherapy
  • Targeted therapy
  • Other therapies

Market, By Drug Class

  • Androgen receptor inhibitors
  • GnRH receptor antagonist
  • PARP inhibitor
  • Immune checkpoint inhibitors
  • Other drug classes

Market, By Route of Administration

  • Oral
  • Injectable

Market, By Distribution Channel

  • Hospital pharmacy
  • Brick and mortar
  • E-commerce

The above information is provided for the following regions and countries:

  • North America
    • U.S.
    • Canada 
  • Europe
    • Germany
    • UK
    • France
    • Spain
    • Italy
    • Netherlands
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Middle East and Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Rest of Middle East and Africa


Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Prostate cancer therapeutics industry size was USD 11.7 billion in 2023 and is projected to expand at 8.8% CAGR from 2024 to 2032, due the ongoing advancements in treatment modalities, and expanding pipeline of novel therapies.

The hormonal therapy segment in the prostate cancer therapeutics industry accounted for USD 8.1 billion in revenue in 2023, as it is effective in reducing levels of androgens (male hormones), such as testosterone.

The androgen receptor inhibitors drug class segment in the prostate cancer therapeutics industry accounted for 35% share in 2023 and is estimated to witness significant growth between 2024 and 2032, owing to their ability to provide therapeutic options to manage CRPC by targeting androgen receptor signaling pathways.

North America prostate cancer therapeutics industry recorded USD 4.6 billion in revenue in 2023 and is projected to grow at 8.4% CAGR from 2024 to 2032, led by the presence of advanced healthcare infrastructure, including well-equipped hospitals, specialized cancer centers, and comprehensive oncology care facilities.

Prostate Cancer Therapeutics Market Scope

Buy Now

Premium Report Details

  • Base Year: 2023
  • Companies covered: 15
  • Tables & Figures: 148
  • Countries covered: 23
  • Pages: 110
 Download Free Sample